Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, discusses what clinicians need to be conscious about regarding the outcomes disparities between adolescents and young adults with acute lymphoblastic leukemia (ALL), and children with ALL.
Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, discusses what clinicians need to be conscious about regarding the outcomes disparities between adolescents and young adults with acute lymphoblastic leukemia (ALL), and children with ALL.
Transcript
In what ways can clinicians be conscious of the outcomes disparities between adolescents and young adults with ALL, and children with ALL?
That’s a really good question. There’s a lot of things that impact this. This is just the tip of the iceberg. We’re going to move forward and really try to figure this out but I think the first thing that clinicians can do is just to be aware that these patients are different from children and they’re different from patients that are over 40 as well. They’re different from their older adults that walk through the door and that really there’s a lot of different things that need to be considered in terms of treatment on a clinical trial and consideration of what kind of treatment they give them.
So really what I think in terms of thinking about these patients, the most important thing is for clinicians to recognize that they’re different from their younger counterparts and from their older counterparts. So when someone walks through your door and and they’re diagnosed with ALL and they’re under 40, I think the most important thing is to think about them as a unique group. Think about the kind of treatment they receive, and really, because of this duration of treatment, think about the kind of treatment you’re giving, and really, keeping them on track and making sure that they finish and don’t fall off at the end, which happens. These patients, sometimes because of all of the psycho-social stressors in their lives, they’re at this very unique time in their lives and there’s so much going on and so they do need psycho-social support in different ways. We haven’t shown this specifically and we really need to take that all into account, though.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More